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Myeloproliferative Disorders
Introduction
Mastocytosis is a rare and clonal hematopoietic disorder
described as the accumulation of abnormal mast cells in the
bone marrow (BM).1,2 In adults, mastocytosis most often pres-
ents as a persistent systemic disorder of variable course and
prognosis.3,4 Disease phenotypes range from indolent to
aggressive and are defined by WHO criteria: mainly B- and C-
findings that describe the extent of organ and tissue damage
resulting from systemic mast cell infiltration. In approximate-
ly 40% of cases, systemic mastocytosis is diagnosed in con-
junction with associated clonal hematologic non-mast cell lin-
eage diseases (AHNMD) which include myelodysplastic syn-
dromes (MDS), myeloproliferative neoplasm (MPN), as well
as both acute and chronic forms of myeloid leukemia (AML,
CML, CMML).4,5
It remains unclear why in some cases mastocytosis evolves
aggressively while in other cases the disease remains indo-
lent. Efforts to discriminate and to predict the clinical course
of mastocytosis have uncovered genetic mutations that figure
prominently in this disease. KITD816V mutation is the most
common (>80% of mastocytosis cases) and is thought to
drive the expansion of affected clones towards the mast cell
lineage,6 but does not segregate with advanced disease. In
contrast, TET2 mutation, found in approximately 20% of
patients, is associated with aggressive forms of mastocytosis.7
Mutations in other epigenetic modifiers have been described,
but so far they have not been clearly associated to any partic-
ular form of disease and, overall, their prognostic relevance is
not clear.8 More recently, a hotspot mutation in SRSF2, a com-
ponent of the RNA splicing machinery, has been identified
and associated with leukemic transformation.9,10 Among
myelodysplastic syndromes and other hematologic disorders,
SRSF2 mutation is most frequent in CMML, with reports
ranging from 28.4% to 47.2%.11 Like TET2, SRSF2 mutation
occurs early in disease ontogeny and has been dubbed a
founder mutation.12 As such, SRSF2 mutation is thought to
pre-dispose early progenitor cells to malignant selection, per-
haps via its role in the acetylation/phosphorylation network
and as an important regulator of DNA stability and mRNA
splicing.13 We have now sequenced for SRSF2 mutation in our
cohort of mastocytosis patients, previously characterized for
both KIT and TET2 mutations,7 and have revealed a striking
association between SRSF2 mutation and advanced disease
types. 
Methods 
Patients’ data
Seventy-two patients (35 men; 37 women) with mastocytosis diag-
nosis as defined by the WHO criteria14 were enrolled in a prospective
national multicenter study between 2005 and 2013. The cohort con-
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ABSTRACT
sists of patients diagnosed with cutaneous mastocytosis (CM),
CM (type TMEP), indolent SM (ISM), systemic mastocytosis with
AHNMD (SM-AHNMD), aggressive SM (ASM), mast cell
leukemia (MCL) and mast cell sarcoma (Online Supplementary Table
S1).1-3 AHNMD diagnosis for each patient has been indicated
(Figure 1), and this is detailed in the Online Supplementary Table S1.
Patients were further grouped using the operational terms
“advanced” and “non-advanced” to account for the number of
patients in certain classifications, e.g. MCL and mast cell sarcoma
that were not large enough for statistical analysis. Statistical analy-
sis of predictive factors (anemia, blast count, thrombocytopenia,
hypoalbuminemia etc.), KIT and TET2 mutation for this cohort
have been presented elsewhere.7 All patients were included in a
mastocytosis pathophysiological study which started in 2003 and
is sponsored by the Association For Initiative and Research on
Mast cell and Mastocytosis (AFIRMM). The study was approved
by the Necker Hospital ethical committee, and carried out accord-
ing to the Declaration of Helsinki. Each patient provided informed
consent. 
Mutation screening
Mutation analysis for KIT and NRAS, KRAS and TET2 has been
described previously.15,16 Other methods have been previously
described as follows: DNA Sanger-sequencing of exon-coding
sequences of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2 and
EZH2,17 SRSF2, U2AF1, ZSRSR2 d,11 and SF3B1.18
Clonal analysis
Leukocytes were purified using FicollR (Sigma) from fresh bone
marrow from patients and plated at low density in methocult
medium (H4035 without Epo, StemCell Technologies). Individual
colonies were isolated at Day 10-12 of culture and DNA was iso-
lated for mutation screening.
FACS sorting
Fresh or frozen whole bone marrow biopsy material from
patients was stained with the following antibody cocktail: anti-
humanCD3-ECD, anti-humanCD14-alexa647, anti-humanCD25-
PE and anti-humanFcepsilonGR1a-FITC (all from BD Biosciences).
Cells were sorted on an LSRII and DIVATM (Becton-Dickinson)
software was used. Sorted cell populations were directly lysed and
DNA was isolated for mutation screening. 
Statistical analysis
Statistical comparisons for predictive factors and mutations
were based on Fisher’s exact test. All reported P values were two-
tailed with confidence intervals of 95%. Survival data were ana-
lyzed using GraphPad Prism software version 5.01 (GraphPad
Software Inc., San Diego, CA, USA) and both the log rank
(Mantel-Cox) and Gehan-Breslow-Wilcoxon tests were applied to
survival curves to determine significant differences.
Results
SRSF2P95 hotspot mutation is highly correlated 
with advanced forms of mastocytosis 
Total bone marrow or peripheral blood was collected
from a cohort of 72 patients with mastocytosis, catego-
rized according to the WHO classification and for
advanced or non-advanced disease (Online Supplementary
Table S1). Biopsied material from these patients was
screened for mutation in genes commonly mutated in
mastocytosis or other myeloid diseases (Figure 1). After
KIT (81%), the SRSF2-P95 hotspot mutation was the most
frequent mutation found in these patients (17 of 72;
23.6%). We detected four different mutations of the
NSRSF2-P95 codon in patients: SRSF2-P95H, SRSF2-P95L,
SRSF2-P95T and SRSF2-P95R (Online Supplementary Table
S1). We have previously reported an association between
TET2 and advanced systemic mastocytosis7 and, like
TET2, we also saw a significant correlation between
SRSF2-P95 mutation and advanced disease (P<0.0001)
(Table 1). Unlike TET2 mutation, that was found only in
patients positive for KIT mutation,7 3 patients who were
negative for KIT mutation were positive for SRSF2-P95
mutation. SRSF2 mutation also coincides significantly
with the presence of AHNMD (15 of 17 patients with
SRSF2-P95 mutation present with AHNMD), but not with
any particular form of AHNMD (Table 2). 
Advanced forms of mastocytosis are associated 
with short overall survival 
Survival curves were generated to compare the survival
of mastocytosis patients with advanced disease versus
non-advanced disease (Figure 2A). We found a significant
reduction in the survival time at diagnosis for patients
diagnosed with advanced forms of mastocytosis
(P>0.001). Since the vast majority of patients with SRSF2-
P95 mutation have advanced disease types, to eliminate
this bias, we next generated survival curves for patients
diagnosed with advanced disease types only to compare
survival time of patients with or without SRSF2-P95 muta-
tion (Figure 2B). We found no significant difference
between the overall survival of patients with advanced
disease and SRSF2-P95 MUT compared to patients with
advanced disease and SRSF2-P95 WT (P>0.5) (Figure 2B).
Taken together, advanced disease diagnosis and not
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Table 1. SRSF2-P95 mutation is correlated with advanced mastocyto-
sis.
Non-advanced Advanced Total P
SRSF2 mutation <0.0001 (F)
N. 41 31 72
WT 39 (95%) 16 (52%) 55 (76%)
P95H/L/R/T 2 (5%) 15 (48%) 17 (24%)
(F) Fisher’s exact test.
Table 2. Contingency analysis for SRSF2-P95 mutation and AHNMD.
SRSF2 WT SRSF2-P95 Total P
Associated disease <0.0001 (F)
N. 55 17 72
no AHNMD 46 (84%) 2 (12%) 48
AHNMD 9 (16%) 15 (88%) 24
Type of AHNMD 0.4731 (C)
N. 9 15 24
CML 1 0 1
AML 1 2 3
CMML 0 4 4
MDS 2 3 5
MSD (AREB) 3 2 5
MPN (SMG myeloid) 1 2 3
MPN/MDS 1 1 2
Waldenstrom 0 1 1
(F) Fisher’s exact test; (C) χ2.
SRSF2-P95 mutation appears to be the dominant factor for
predicting shorter overall survival times in patients.
Interestingly, 3 patients positive for SRSF2-P95 mutation
at the original time of diagnosis developed an AHNMD
during the course of this study (within 2 years). Patient n.
M40 originally diagnosed with SM developed AHNMD
(MDS), Patient n. 1318 originally diagnosed with ISM pro-
gressed to SM-AHNMD, and Patient n. D60 originally
diagnosed with ASM developed MCL (Figure1, dotted
boxes, and Online Supplementary Table S1).
SRSF2-P95 mutation is significantly associated with
mutations in epi-regulators
In addition to KIT and SRSF2-P95, amplicon screening
was also performed for other known mutations: SF3B1,
U2AF1 and ZRSR2 (splicing factors), TET2, IDH1, IDH2,
AXSL1, DNMT3A, EZH2 (epigenetic regulators), as well as
JAK2, CBL, NRAS and KRAS (Figure 1 and Online
Supplementary Table S1). 
Generally, more mutations were found in patients with
advanced disease than patients with non-advanced dis-
ease. After KIT, SRSF2-P95 and TET2 mutation were by
far the most frequent mutations found in patients: 24%
and 21%, respectively. Interestingly, statistical analysis
shows that TET2 mutation is significantly correlated to
SRSF2-P95 mutation in these patients (P<0.01) (Table 3),
and an even more significant correlation is found when
mutations in epigenetic factors are considered as a whole
(mutation of SRSF2 in combination with at least one epi-
genetic factor; P<0.0001). 
Consistent with a previous report showing that SF3B1
mutations are infrequent in mast cell diseases,19 SF3B1
mutations were detected in only 4 (5.6%) of our patients:
2 patients had mutations in exon 14 (codon 666 and the
other at codon 663), and 2 patients had mutations in exon
15. We also identified 2 patients with mutation in U2AF1
(both at codon 101 in exon 2). Interestingly, mutations in
splicing factors SRSF2, SF3B1 and U2AF1 are mutually
exclusive in these patients (Figure 1 and Online
Supplementary Table S1). 
SRSF2-P95 mutation is present in mast cells
Given the strong association between SRSF2 mutation
and AHNMD, to ensure that the SRSF2 mutation was
present in the mast cell component of the disease, we sort-
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Figure 1. The frequencies and distribution of 10 gene mutations in 72 patients with mastocytosis. Each column represents one individual
patient with mutated gene(s) shown by different colored bars. The last two rows describe the disease classification for each patient. Half
boxes reveal evolved diagnosis during the course of this study and dotted lines highlight those patients with SRSF2-P95 mutation and disease
evolution. No mutations were found for ZRSR2, KRAS, IDH1, DNMT3A or EZH2.
Figure 2. Survival proportions of patients with advanced forms of
mastocytosis. (A) Percent survival of patients with advanced disease
type and non-advanced disease type in years post-disease diagnosis.
(B) Percent survival of patients with advanced disease phenotype,
with or without SRSF2-P95 mutation (Adv SRSF2-P95 MUT or Adv
SRSF2-P95 WT), in years post-disease diagnosis. P-values were cal-
culated using the log rank (Mantel-Cox) test. 
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ed cell populations from total bone marrow of 7 patients
with advanced disease phenotypes for genotype analysis
(Figure 3A). Genomic DNA from the three collected pop-
ulations, T cells, monocytes and mast cells was isolated
and genotyped for KIT, TET2 and SRSF2 mutations
(Figure 3B). In all 7 patients for whom sorted populations,
KIT, SRSF2 and TET2 mutations, were detected in whole
bone marrow biopsies (Online Supplementary Table S1) as
well as in the mast cell and monocyte compartments. In all
patients, KIT, TET2 and SRSF2 mutations were variably
present in T cells, depending on when, during hematopoi-
etic differentiation, the individual mutations were
acquired. For patient M40, in whom KIT mutation was
not detected, we detected JAK2 V617F mutation in mast
cells and monocytes, but not in T cells. Finally, in patients
presenting with two different TET2 mutations, both
mutations were present in positive cell populations.
Interestingly, in one patient (Patient n. 1445), we detected
SRSF2mutation in T cells where TET2 and KITmutations
were present only in mast cells and monocytes. 
SRSF2-P95 mutation can occur early or late during
clonal evolution 
To determine the relative timing of SRSF2mutation dur-
ing clonal evolution, we examined individual colonies
derived from total bone marrow of 2 patients with
advanced disease and KITD816V, TET2 and SRSF2-P95
mutations. Mutational analysis of single colonies distin-
guished three different patterns of mutation accumulation
(Figure 3C, arrows). In both patients, we identified clones
harboring TET2 mutation alone, TET2 and SRSF2, TET2
and KIT or all three mutations. These data are consistent
with TET2mutation preceding both SRSF2 and KITmuta-
tion in both patients, and either SRSF2 or KIT mutation
occurring next. Interestingly, where mutation screening of
whole bone marrow for Patient n. F50 identified
SRSF2-P95 mutation is associated with ASM and AHNMD
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Table 3. Contingency analysis for SRSF2-P95 mutation and Epi-regu-
lator mutations.
SRSF2 WT SRSF2-P95 Total P
Tet2 mutation 0.0049 (F)
N. 55 17 72
WT 48 (87%) 9 (53%) 57
MUT 7 (13%) 8 (47%) 15
Epi-regulators* <0.0001 (F)
N. 55 17 72
at least 1 9 (16%) 13 (77%) 22
0 46 (84%) 4 (23%) 50
(F) Fisher’s exact test; *TET2, IDH1/2, ASXL1.
Figure 3. SRSF2, TET2 and KIT status
of sorted cell populations for 7
patients with ASM. (A) Total bone
marrow of 7 patients with advanced
disease phenotypes were FACS sort-
ed using lineage-specific antibodies.
Figure shows a representative FACS
profile from one patient. (B) DNA was
isolated from the three collected pop-
ulations, T cells, monocytes and mast
cells and genotyped for KIT, TET2 and
SRSF2 mutation. (C) Analysis of sin-
gle colonies for mutations in SRSF2,
TET2 and KIT. Single colony-forming
units derived from mononuclear cells
of whole bone marrow, were isolated
and analyzed individually for the pres-
ence of SRSF2, TET2 and KITD816V
mutations. Each colony is represent-
ed by a dot that is placed in boxes
according to genotype. The unique
patient numbers and the diagnoses
are shown above the corresponding
boxes. Light gray arrows indicate the
suggested order of mutation events.
A black dot indicates that SRSF2-
P95H mutation was detected rather
than SRSF2-P95L.
Monocytes
CD3
Patient: F50 (ASM-AHNMD)
SRSF2P95L
SRSF2P95H SRSF2
P95H
SRSF2WT SRSF2WT
Patient: V20 (ASM-AHNMD)
FceRa1
T-cells
CD
14
CD
25
Mast cells
A
B
C
KITWT KITWT KITD816V
TET2WT TET2Q1389* TET2Q1389*
KITWT KITWT KITWT KITWT KITD816BV
TET2WT TET2Q734* TET2M1800D TET2M1800D TET2M1800D
TET2Q734* TET2Q734*
KITD816V, TET2 Q1389* and SRSF2-P95L mutations
(Online Supplementary Table S1), clonal analysis revealed 5
of 14 colonies harboring a distinct SRSF2-P95H mutation.
Both SRSF2-P95L and SRSF2-P95H colonies harbored
TET2 Q1389* mutation, but only SRSF2-P95L colonies
were positive for KITD816V mutation. 
Discussion
We now report that the SRSF2-P95 hotspot mutation is
highly correlated with advanced forms of mastocytosis,
and, in contrast to TET2, is associated almost exclusively
with, and might predict, the onset of AHNMD. 
We also find a small number of patients negative for the
SRSF2-P95 mutation but harboring a mutation in another
splicing factor, either SF3B1 or U2AF1. Combined,
spliceosome mutations were found in as many as 32% of
patients, pointing to a pathogenic role for abnormal RNA
splicing in SM. In addition to its role as an SR protein in
promoting alternative exon inclusion and integrating other
steps in RNA metabolism,20 a unique role for SRSF2 has
been described in regulating PolII pausing and elongation
at promoters.21,22 SF3B1 is part of a much larger complex
associated with the catalytic activity of the spliceosome,
and U2AF1 is an auxiliary U2-factor involved in splice-site
recognition. So far, among these factors, only U2AF1 has
been directly associated with the deregulated splicing of a
specific, cancer relevant target: EZH2.23 Future studies to
address the global or specific role of gene splicing in hema-
tologic diseases should be informative in dissecting the
molecular contribution of SRSF2 and other splicing muta-
tions in these contexts.
Extensive mutation analysis of this cohort has also
revealed an association between SRSF2 mutation and
mutation in genes whose products function in modifying
the epigenome (epi-regulators), including TET2. This is
consistent with a previous report showing an association
between spliceosome mutations and mutations in epige-
netic modifiers.24 Mechanistically, splicing is often tightly
coupled with transcription and recent work suggests that
alternative splicing might be affected by chromatin struc-
ture and histone modification.25 Together with their role in
regulating DNA stability, it is interesting to speculate that
SRSF2 and epigenetic modifier mutations may act syner-
gistically to promote advanced disease. At present, how-
ever, it is unclear why these mutations coincide with such
high frequency.
Interestingly, from a clinical perspective, 3 patients with
SRSF2-P95 mutation were re-diagnosed with more severe
disease and AHNMD during the course of this study.
Pursuant to reports of an association between SRSF2
mutation, poor prognosis and leukemic progression of
MPNs,26,27 these cases may provide support for a prognos-
tic relevance of SRSF2-P95 mutation in mast cells and in
predicting advanced disease progression. A longer follow
up for the 2 patients with SRSF2-P95 mutation and no
AHNMD, as well as screening in all new patients for
mutation in splicing factor genes, will be necessary to val-
idate this hypothesis. Indeed, here we have validated our
sequencing results from whole bone marrow using sorted
primary mast cells for a subset of patients. However, the
advent of deep sequencing methods will in the future be
important and allow for more sensitive screening for
mutations in mastocytosis patients using whole bone mar-
row, even when the mast cell burden in the bone marrow
is low.  By this approach, we may also reveal a larger num-
ber of mutations in patients with non-advanced disease to
better address issues of specific mutations and their prog-
nostic relevance. 
Importantly, where SRSF2 mutation has previously
been associated with diseases relevant to AHNMD,26
mutation analysis of sorted cell populations from the bone
marrow of mastocytosis patients shows that SRSF2-P95
mutation is present in both mast cells and monocytes
from the bone marrow, supporting a role for SRSF2-P95
mutation in mast cell transformation and possibly a clonal
relationship between the ASM and myeloid AHNMD
components of this disease. 
Finally, our previous analyses using clonal and sorted
cell populations isolated from patient bone marrow, sug-
gested that TET2 mutation occurs prior to KIT mutation
during clonal evolution of advanced forms of mastocyto-
sis.7 By this same approach, we now find that SRSF2
mutation can occur relatively late during the ontogeny,
while in other cases this can precede both TET2 and KIT
mutation. We find evidence to support both: 1) a clone
harboring two mutations TET2, KITD816V but wild type
for SRSF2 was isolated from total bone marrow of a
patient with advanced disease and positive for all three
mutations in the mast cell compartment (Figure 3B and C;
Patient n. F50); and 2) SRSF2-P95 mutation was detected
in all cell types from a patient in whom TET2 and KIT
mutation were detected in only mast cells and monocytes
(Figure 3B; Patient n. 1445). In this case, for SRSF2-P95
mutation to be present in T cells, the mutation must have
occurred either independently or else in a common pro-
genitor, upstream of both TET2 and KIT mutation. Since
all three mutations are detected in both the mast cell and
monocyte (AHNMD) components of the disease, it is
unclear from these results whether clonal evolution favors
one pattern over the other in different cell types. Finally,
not only do these results reveal different patterns of muta-
tion hierarchy and potentially multiple clones in a single
patient, but they also suggest the possibility of parallel
development of different diseases (mastocytosis and
AHNMD). 
Overall, we have performed a comprehensive screen for
mutations previously associated with myeloproliferative
disorders within our large cohort of mastocytosis patients.
We report that, in addition to TET2 mutation, mutation of
the spliceosome factor SRSF2, is also frequent and corre-
lates to advanced disease. In contrast to previous studies,
our patient cohort contains a significant number of both
advanced and non-advanced cases, and as such this study
has a high clinical importance. Moreover, statistically,
these two mutations are strongly associated, suggesting
that in addition to their known functions during differen-
tiation, a mechanistic link between spliceosome and epi-
genetic regulators could promote transformation in vivo. 
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